Slide 1: Presentation Financial Statements 31 December 2022
PRESENTATION FINANCIAL STATEMENTS 31 December 2022
Slide 2: About this Presentation
About this Presentation Presenting the financial statements to shareholders is essential to provide a clear and detailed picture of the company's financial position. These presentations should provide a comprehensive view of the company's financial performance and should provide shareholders with th
Slide 3: Company Details
Company Details Brand: Name of the commercial company: Biofarm S.A. Main object of activity: Manufacture of pharmaceutical preparations Registered office: Str. Logofătul Tăutu nr. 99, Bucharest, sector 3 Production units: Str. Logofătul Tăutu nr. 99, Bucharest, sector 3 Str. Drumul Gura Bădicului nr
Slide 4: About us
About us The most famous Biofarm® brands have written history, and the fact that after so It is precisely this expertise and permanent consultation of our consumers that forces us to go 101 years of life have taught us many things: many years since their appearance they are further and expand our ra
Slide 5: History
History 1964 1928 1956 1959 1965 1978 1921 Cavit 1969 Carmol Year of Expansion Triferment & Anghirol Colebil Insulin Production The oldest stories about Cavit Year of At a time when the Two of the most famous are already 5 decades old and Year of Biofarm Establishment pharmaceutical industry Biofarm
Slide 6: General Manager's Declarations
General Manager’s Declarations “By understanding the lifestyle and social contexts of employees, the company is committed to meeting their needs. Thus, the increase in expenses related to salaries for 2022 represents one of the company's efforts to show its care towards them. Innovation is part of B
Slide 7: Mission, vision and values
Mission, vision and values Our Vision Our Mission Our vision is for Biofarm ® products to be the first The mission of Biofarm® is to do good to those around choice for those who want well-being and are us through continuous improvement, with respect for concerned about their health, because we, at B
Slide 8: Responsibility towards our consumers
Responsibility towards our consumers guides us in every action we undertake and in every business decision. We treat each consumer and the health problem they We think responsibly and feel responsible for each face with care and respect, we accompany all those person who uses a Biofarm product. The
Slide 9: Certificates
Certificates Biofarm SA is an authorized manufacturer of pharmaceutical preparations with 2 operational units. In June 2021, the new production unit in Strada Drumul Gura Bădicului nr. 202-232, Bucharest, sector 3 was inspected by ANMDMR (National Agency for Medicines and Medical Devices of Romania)
Slide 10: Brands
Brands The brands of Biofarm were created to respond to the needs and expectations of our customers, differentiating our own products from those of competing companies. They create recognition, give value to the product and the company, and are a promise of quality, professionalism, efficiency and a
Slide 11: Brands
Brands Biofarm S.A. is one of the first ten manufacturers of drugs and food supplements in Romania. In more than 100 years of uninterrupted activity, Biofarm has always focused on aligning with market requirements and patient’s needs, being a company always oriented towards innovation and facilitati
Slide 12: Biofarm Performance
Biofarm Performance The performance of our company is mainly determined by the following: Stock Exchange Financial Evolution Evolution Strategic Development 12
Slide 13: Strategic Development: Worldwide Strategy
Strategic Development Worldwide Strategy Maintaining and strengthening the worldwide strategy is proving effective and relevant to our business. Thus, the global strategy remains unchanged and begins by prioritizing strategic initiatives for the greatest business impact. Establishing global brands,
Slide 14: Strategic Development: Local Strategy
Strategic Development Local Strategy Our attitude is ecological and helps us bring innovation and know-how to our customers, but also to set new standards on the local market in terms of high quality and sustainability. We work every day and do everything in our power to help transform this sector i
Slide 15: Strategic Development
Strategic Development It is important for Biofarm to consider the threats and risks associated with global warming in their business strategies, adopt sustainable practices and develop adaptation plans to deal with climate change. Global warming is an ongoing threat to commerce, with the potential t
Slide 16: Strategic Development
Strategic Development Biofarm's strategy is dynamic, adaptable and accessible to everyone in our field of activity. Strategy development is an iterative, continuous, collaborative process that constantly considers how to optimize each step from the planning phase to its successful execution. 2022 wa
Slide 17: Strategic Development: OTC products
Strategic Development In 2022, in terms of value, Biofarm is still on the 5th place in the top sales of pharmaceutical companies in Romania for the category of products that are released without a medical prescription (OTC). For the OTC category, Biofarm is No. 1 in the therapeutic class for: BIXTON
Slide 18: Strategic Development: food supplements
Strategic Development In terms of value, Biofarm is the fourth largest pharmaceutical company in Romania for the food supplement product category (FS). For the FS category, from the point of view of value, Biofarm is on first place in the therapeutic class for: EXTRAVALERIAN, LACTIC CALCIUM and on t
Slide 19: Strategic Development: prescription products
Strategic Development For the Prescription Products (RX) category, Biofarm is No. 1 in therapeutic class for: VITAMIN A and is No. 2 in therapeutic class for COLCHICINE. RX products from the Top 10 Biofarm portfolio, based on the value of registered sales, include the following: Crt. Brand Common in
Slide 20: Financial Evolution: Profit and loss account
Financial Evolution Profit and loss account and other income The net income from sales in 2022 was of lei 276,982,692, increasing by 16%, as compared to 2021. The net operating result for 2022 increased by approximately 13%, as compared to 2021, while the company's net profit saw the same increase o
Slide 21: Financial Evolution: Assets, debts and equities
Financial Evolution Statement of assets, debts and equities In 2022, the value of ongoing purchases of tangible assets was of lei 25,174,761. Tangible assets, respectively "Technical installations and machines" increased by lei 14,302,488 due to the commissioning of new production equipment necessar
Slide 22: Financial Evolution: Capital
Financial Evolution Statement of Financial Position – Capital The subscribed share capital of the company as at 31 December 2022 was of lei 98,537,535, the nominal value of a share was of lei 0.1/share. The company has a number of 985,375,350 shares that give equal rights to the company's shareholde
Slide 23: Financial Evolution: Statement of cash flows
Financial Evolution Statement of cash flows Most of cash flows are generated from the company's core activity, the production and marketing of medicines for human use, NACE code 2120 "Manufacture of pharmaceutical preparations". During 2022, Biofarm SA generated a cash inflow from operating activiti
Slide 24: Information about the Stock Exchange
Information about the Stock Exchange Biofarm has been present on the Romanian market for 101 years and maintains its motivation to increase the quality of people's lives, being a company always oriented towards innovation and facilitating access to modern treatment solutions. The securities issued
Slide 25: Information about the Stock Market
Information about the Stock Market The shares of BIOFARM S.A. were traded on the RASDAQ Market, in the basic category, starting from 19.11.1996. In accordance with the Decision of the Extraordinary General Meeting of Shareholders No. 40 of 24.03.2005, the start of the necessary operations for the co
Slide 26: Evolution on the Stock Exchange
Evolution on the Stock Exchange After the highest historical quotation reached at the end of 2021, in the second half of 2022, the stock exchange quotation stabilized around the value of 0.6 lei/share (+/-10%). On 31 December 2022, the closing price of the year was of lei 0.61/share, 26% below the o
Slide 27: Information about dividends
Information about dividends Policy of Dividends The company's policy on the distribution of net profit was updated during 2022 and aims, depending on the options, to distribute it to shareholders, to reinvest it in supporting its projects or to distribute it to both destinations. Annually, the compa